The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Pharmacologic management of weight regain following bariatric surgery.
Open accessAbstract
While bariatric surgery restults in significant long-term weight loss for most patients with obesity, post-surgical weight gain affects a considerable percentage of patients to varying degrees of severity. Furthermore, a small but significant percentage of patients experience inadequate post-surgical weight loss. Although many studies have examined the role of anti-obesity medications to address post-operative weight regain, an evidence-based consensus has not yet been achieved because of the heterogeneity of populations studied and the studies themselves. Observational studies in the post-bariatric surgery population consistently demonstrate the benefit of medical weight management after bariatric surgery, with most evidence highlighting liraglutide, topiramate, and phentermine/topiramate. New anti-obesity medications are anticipated to be helpful for post-surgical weight optimization given their efficacy in the non-surgical population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RYGB appears to increase risk of later alcohol-related problems, although it is uncertain whether SG confers similar risk.114”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery
Sjöström, L., Lindroos, A.-K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., Dahlgren, S., Larsson, B., Narbro, K., Sjöström, C. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035622 · Cited by 4,457
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Pharmacotherapies with gut peptide modulators are emerging as the most effective AOMs (44, 45), with the most recent addition, tirzepatide 15 mg, demonstrating about 20% average weight loss, greater than lap band but less than sleeve gastrectomy and gastric bypass (38).”
BackgroundSelf-citationFuller, N. R., Colagiuri, S., Schofield, D., Olson, A. D., Shrestha, R., Holzapfel, C., Wolfenstetter, S. B., Holle, R., Ahern, A. L., Hauner, H., et al. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.139 · Cited by 2,117
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835 · cited 2×
“Weight regain after bariatric surgery most often begins 1-2 years post-operatively (3).”
BackgroundDavies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Cited by
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Semaglutide for weight loss: unanswered questions
Tzoulis, P., & Baldeweg, S. E. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1382814 · Cited by 30
“Ongoing prospective studies, such as the BARI-STEP trial, aim to determine the role of semaglutide in individuals who have experienced insuf fi cient weight loss or excessive weight regain following bariatric surgery (47, 48).”
BackgroundNie, Y., Zhang, Y., Liu, B., & Meng, H. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07733-8 · Cited by 30
“Although there is currently no standardized timing for the initiation of GLP-1 RAs, existing clinical evidence suggests that early administration following the diagnosis of SICR or WGR is beneficial [66].”
Pharmacotherapy before and after bariatric surgery
Alabduljabbar, K. A., & le Roux, C. W. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155692 · Cited by 30
Rubio, M. Á., Carreiro, S. M., Sánchez-Pernaute, A., & Ramos-Levi, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11102785 · Cited by 28
“Pharmacological treatment for obesity has been mainly focused on the setting of in-sufficient or inadequate postsurgical weight loss, weight plateau, or post-surgical weight regain [8–10].”
Background
Metadata
- Authors
- Lucas, E., Simmons, O., Tchang, B., & Aronne, L.
- Affiliations
- Weill Cornell Medical Center (US)
- Corresponding author
- Lucas, Eugene
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-09
- Volume
- 13
- Pages
- 1043595-1043595
- ISSN
- 1664-2392 (ISSN-L)
- PMC
- PMC9868802
- OpenAlex
- W4317242712
- Cited by
- 41
- References
- 52
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 16 · 2023: 5
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Body Contouring and Surgery
- Keywords
- bariatric surgery, postoperative weight regain, obesity, anti-obesity drugs, liraglutide, topiramate, phentermine/topiramate
- MeSH terms
- Topiramate, Humans, Obesity, Morbid, Weight Gain, Weight Loss, Anti-Obesity Agents, Bariatric Surgery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic management of weight regain following bariatric surgery. https://app.cochat.ai/papers/10.3389/fendo.2022.1043595
- The paper
- Lucas, E., Simmons, O., Tchang, B., & Aronne, L. (2023). Pharmacologic management of weight regain following bariatric surgery. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1043595
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
